Helen Torok, MD

home / authors / helen-torok-md

Helen M. Torok, MD, is the medical director of the Trillium Creek Dermatology Center.

Articles

Editorial Advisory Board Insights for Eczema Awareness Month: Helen Torok, MD

Emma Andrus, Associate Editor;Helen Torok, MD

October 24th 2023

Helen Torok, MD, shares her atopic dermatitis insights.

Plaque Psoriasis Management: Future Directions in Care

Christopher G. Bunick, MD, PhD;Helen Torok, MD;Mark G. Lebwohl, MD;Jashin Wu, MD

February 7th 2022

Closing out their discussion on the management of plaque psoriasis, panelists share their excitement for future directions in care.

Biologic Therapy in Plaque Psoriasis: Treating During the COVID-19 Pandemic

Christopher G. Bunick, MD, PhD;Mark G. Lebwohl, MD;Jashin Wu, MD;Helen Torok, MD

February 7th 2022

Experts reflect on the treatment of patients with plaque psoriasis during the COVID-19 pandemic.

Unmet Needs in Moderate to Severe Plaque Psoriasis Management

Christopher G. Bunick, MD, PhD;Mark G. Lebwohl, MD;Jashin Wu, MD;Helen Torok, MD

January 31st 2022

A brief discussion on the unmet needs and ongoing challenges in the treatment of plaque psoriasis.

Plaque Psoriasis Patient Case 2: Factors in Selecting 2L Therapy

Christopher G. Bunick, MD, PhD;Mark G. Lebwohl, MD;Jashin Wu, MD;Helen Torok, MD

January 31st 2022

Shared insight on which factors are most important in determining second-line therapy for plaque psoriasis.

Plaque Psoriasis Patient Case 2: Switching Therapy at Treatment Failure

Christopher G. Bunick, MD, PhD;Mark G. Lebwohl, MD;Jashin Wu, MD;Helen Torok, MD

January 24th 2022

Moving on to the second patient case, panelists discuss switching therapy at treatment failure for plaque psoriasis.

Factors in Selecting Biologic Therapy for Moderate to Severe Plaque Psoriasis

Christopher G. Bunick, MD, PhD;Mark G. Lebwohl, MD;Jashin Wu, MD;Helen Torok, MD

January 24th 2022

Panelists share which factors they use to determine optimal therapy in the moderate to severe plaque psoriasis setting.

Plaque Psoriasis: Biologic Therapy Toxicity Profiles

Christopher G. Bunick, MD, PhD;Mark G. Lebwohl, MD;Jashin Wu, MD;Helen Torok, MD

January 17th 2022

A panel of experts reflect on the toxicity profiles of biologic agents used to treat patients with plaque psoriasis.

Bimekizumab’s Potential in Moderate-to-Severe Plaque Psoriasis

Christopher G. Bunick, MD, PhD;Mark G. Lebwohl, MD;Jashin Wu, MD;Helen Torok, MD

January 17th 2022

A focused discussion on the benefit of bimekizumab, an IL-17A/IL-17F inhibitor, in the setting of moderate to severe plaque psoriasis.

Moderate to Severe Plaque Psoriasis: An Overview of Biologic Agents

Christopher G. Bunick, MD, PhD;Mark G. Lebwohl, MD;Jashin Wu, MD;Helen Torok, MD

January 10th 2022

A brief review of biologic agents being used or evaluated in the setting of plaque psoriasis.

Moderate to Severe Plaque Psoriasis: What is the Standard of Care?

Christopher G. Bunick, MD, PhD;Mark G. Lebwohl, MD;Jashin Wu, MD;Helen Torok, MD

January 10th 2022

Taking a broader look at moderate to severe plaque psoriasis, experts consider what the standard of care would be in different settings.

Plaque Psoriasis Case 1: Selecting a Therapeutic Class

Christopher G. Bunick, MD, PhD;Mark G. Lebwohl, MD;Jashin Wu, MD;Helen Torok, MD

January 5th 2022

The panel reviews therapeutic classes and their respective benefits in patients being treated for plaque psoriasis.

Plaque Psoriasis Case 1: Patient Counseling and Approaching Therapy

Christopher G. Bunick, MD, PhD;Mark G. Lebwohl, MD;Jashin Wu, MD;Helen Torok, MD

January 5th 2022

Centering discussion on a case of plaque psoriasis, experts share their experience with patient counseling and selecting therapy.

Understanding the Psychosocial Burden of Plaque Psoriasis

Christopher G. Bunick, MD, PhD;Mark G. Lebwohl, MD;Jashin Wu, MD;Helen Torok, MD

December 23rd 2021

Considerations for the psychological and social impact that plaque psoriasis may have on a patient.

Challenges in Diagnosing Plaque Psoriasis

Christopher G. Bunick, MD, PhD;Mark G. Lebwohl, MD;Jashin Wu, MD;Helen Torok, MD

December 23rd 2021

Panelists look deeper into the possible challenges or barriers to making an accurate diagnosis of plaque psoriasis

Identifying Clinical Manifestations of Plaque Psoriasis

Christopher G. Bunick, MD, PhD;Mark G. Lebwohl, MD;Jashin Wu, MD;Helen Torok, MD

December 16th 2021

Shared insight on identifying clinical manifestations of plaque psoriasis and making a timely diagnosis.

Pathophysiology of Plaque Psoriasis and Targeted Therapies

Christopher G. Bunick, MD, PhD;Mark G. Lebwohl, MD;Helen Torok, MD;Jashin Wu, MD

December 16th 2021

A panel of experts review the nature of plaque psoriasis and the mechanism of action of several classes of targeted therapy.

Administrative Burden of Prescribing Biologics

Aaron Funk;Matthew Reedy, MD;Helen Torok, MD

May 21st 2021

Prescribing biologics can require a complex approval and claims process. Creating a tiered system based on office workload can help practices understand and allocate staff time. Outsourcing approvals to pharmacies where possible can also streamline the process.

Social networking: Implement popular Internet trend into your daily practice

Helen Torok, MD

October 1st 2009

As a physician, I am starved for time. Social networking sites allow me to get the medical information I need quickly and efficiently. I can chat with other colleagues on cases, as well as learn about new products and services coming down the pike.

The enemy of great is good

Helen Torok, MD

January 1st 2007

The challenge is to select the information and technology that is promising and practical.